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ABSTRACT
This descriptive observational study was conducted to increase understanding of medication administration practices
during actual clinical use between 2 commonly used, different types of intravenous (IV) smart pumps. Compliance
with manufacturer-recommended setup requirements for both primary and secondary infusions and secondary
medication administration delay was compared between a head-height differential system and a cassette system. A
total of 301 medication administration observations were included in this study: 102 (34%) for the linear peristaltic IV
smart pump (medical–surgical: N = 51; critical care: N = 51) and 199 (66%) for the cassette pump (medical–surgical:
N = 88; critical care: N = 111). Results found a 0% compliance for primary line setup and 84% compliance for secondary line setup and 1 omitted medication due to a closed clamp with the linear peristaltic system. For the cassette
system, there are no head-height requirements. Two roller clamps were found to be in the closed position on initiation of the secondary infusion, but the clinician was alerted by an alarm, so no medication delays occurred. These
findings support that the current system requirements for flow rate accuracy using head-height differential systems
are difficult to achieve consistently at the point of care. There is a need for additional human factor designed technology to replace manual actions to improve the process of care for nurses and the safety of care for patients.
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ith an estimated 90% of hospitalized patients
receiving intravenous (IV) medications, IV infusion pumps are ubiquitous in health care.1
Although there are different types of infusion
pumps, large-volume IV smart pumps are the most widely
used in US acute care hospitals because they can administer
large amounts of both fluids and medications.2-4 Through
our experiences as practicing nurses, we know the difficulty
first hand in trying to juggle multiple patient care tasks while
simultaneously having to safely administer potent IV medications with significant potential side effects. The reality of programming an IV smart pump is that the delivery of even a single dose of medication involves multiple steps and keystrokes,
each of which introduces a potential opportunity for error. A
recent study compared some of the differences in IV smart
pump usability with various brands of IV smart pumps and
examples of findings were that the time to power on ranged
from 7.1 to 13.8 seconds, and the number of keystrokes
required to initiate a primary infusion ranged from 10 to 17.5
IV smart pumps have built-in drug libraries, interchangeably referred to as a dose error reduction system or dose
error reduction software (DERS), which are intended to
reduce medication administration errors. These errors are
mitigated by drug-associated DERS programming limits,
which provide various alerts to users if the programmed dose
is outside of the acceptable range. Soft dosing limits provide
a warning that the dose may be out of the acceptable range,
but this limit can be bypassed by the user. When hard-dosing limit alerts are triggered, the IV smart pump must be
reprogrammed to a different dose before the IV medication
administration can proceed. While data support that the use
of IV smart pumps has been associated with reductions in
medication administration errors, they have not eliminated
errors, including serious adverse drug events with high-alert
medications.6-12 High-alert medications are defined by the
Institute for Safe Medication Practices (ISMP) as medications
that bear a heightened risk of significant patient harm when
used in error.13 In our previous research, we found the majority of IV smart pump alerts were bypassed by clinicians at the
point of care, regardless of whether the medication was high
alert or non-high alert, a symptom of alert fatigue and a clear
limitation of IV smart pump safety features.14,15 Considering
the frequency and importance of IV medication administration in acute care, it is noteworthy that few studies have
investigated the root causes of these serious adverse drug
events and whether differences in medication administration
errors exist among different IV smart pump types.
Of the work that has been done, weight-based infusions,
secondary infusions, and IV boluses have been identified as
particularly high risk and error prone.2,16 These IV medication

administration tasks place additional cognitive demands
on users, are not well standardized within hospital protocols, vary among IV smart pump user interfaces, and have
associated failure modes that are not easily detected.16
Unfortunately, available data comparing the workflow and
usability for the user interfaces of different IV smart pump
types are scarce.3,16,17 As a result, limited empiric data exist
about what can and should be required by manufacturers to
help make their products safer and easier to use.
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SECONDARY MEDICATION
ADMINISTRATION
Secondary medication infusion by large-volume IV smart pump
is used extensively in US acute care for administering IV medications ordered for one-time or intermittent dosing. Secondary
administration is designed to allow the primary continuous infusion to pause during the secondary infusion and then resume
automatically after the secondary infusion is complete.16-18
In US acute care, anti-infectives and electrolyte replacement for adult patients are commonly delivered by secondary infusion. Secondary medications are often time
sensitive, and the following are examples of potentially
serious clinical consequences that can result from secondary medication administration delay:
• In a patient receiving an antibiotic as treatment for sepsis, antibiotic administration delay is associated with increased mortality.19,20
• For patients receiving an antibiotic to prevent surgical
site infection (SSI), a delay results in increased SSI risk, a
common hospital-acquired infection.21
• For patients receiving crucial electrolyte replacements, such
as magnesium or potassium replacement, numerous serious consequences, including cardiac arrest, are possible.

HEAD-HEIGHT DIFFERENTIAL SYSTEM
Secondary medication administration using a head-height
differential system requires a head-height differential
between the primary and secondary fluid containers and
a primary line back-check valve. Head-height differential
refers to the difference between the top of the fluid level
in the primary and secondary fluid containers. With a US
market share of >50%, the Becton Dickinson (BD) Alaris
Pump (Becton, Dickinson and Company, Franklin Lakes, NJ)
is the most common large-volume IV smart pump using this
technique.4,22 The setup requirements are described below
and also shown in Figure 1.23
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Because the medication administration process using
linear peristaltic pumps has so many manual setup requirements, secondary infusions in particular are prone to
user errors.2,16,17 If setup specifications are not adhered
to during clinical use, the secondary medication may not
infuse at all, may infuse into the primary bag instead of the
patient, or may infuse concurrently into the patient with
the primary at a different rate than intended. Furthermore,
all reported flow rate accuracy testing results (±5%) provided with the product labeling and included in regulatory
submissions are obtained using the manufacturer’s setup
specifications. Data support that deviations from manufacturer recommendations decrease both flow rate and flow
rate accuracy.16,17,24
Three specific secondary infusion setup errors that have
been found to occur include:1,2,16,17,25

Figure 1 Required components for secondary medication infusion
using the head-height differential method. Figure used with permission from Karen K. Giuliano, PhD, RN.

1. The IV smart pump is placed on the IV pole in a position that
is level with the patient’s heart, and the top of the fluid in the
primary container is 20 inches above the top of the pump.23
2. A head-height differential of at least 9.5 inches between
the primary fluid level and secondary fluid level for IV
bags and a head-height differential of at least 9.5 inches between the primary fluid level and the fluid level in
the drip chamber for vented IV bottles are required for
adequate infusion. These head-height differentials are
achieved by lowering the primary with a hanger and are
necessary to create the hydrostatic pressure differential
required for secondary medications to infuse.
3. If the secondary container is >50 or 100 mL or the flow
rate is high, it is recommended to check the primary container for flow and, if necessary, add a second hanger to
further lower the primary container.
4. The hydrostatic pressure differential closes a back-check
valve in the primary tubing, which is required to prevent unintended primary flow or reverse flow from the secondary container into the primary container instead of into the patient.
5. The roller clamp on the secondary tubing should be open
during secondary infusion and closed during the primary infusion. If the roller clamp is inadvertently closed
during secondary infusion, no pump alarm will sound,
and the fluid will be pulled from the primary bag at the
programmed secondary flow rate.

1. The use of tubing without a primary line back-check
valve, which can cause backflow into the primary bag instead of directly into the patient.
2. Back-check valve failure because of inadequate headheight differentials, high secondary flow rates, and partial opening of needle-free connectors. All of these conditions may lead to unintended flow from the primary
container or backflow into the primary bag instead of
directly into the patient.
3. Leaving the roller clamp closed, which prevents the secondary medication from infusing at all.
Following is an example from the US Food and Drug
Administration (FDA) Manufacturer and User Facility Device
Experience database, which provides an example of backcheck valve failure.
“The patient was to receive IV albumin piggybacked onto a
normal saline infusion through an infusion pump. The nurse
set up the infusion. When she checked in on the patient
approximately 20 minutes later, she noted that the bottom
of the saline bag had discolored to amber brown, indicating
that the albumin was emptying out of the piggybacked bag
and flowing into the primary bag. The piggybacked infusion
had been set up correctly, with the secondary bag hung
higher than the primary bag. The back-check valve in the
primary tubing should have prohibited flow of the secondary infusion into the primary bag.”26

In this case, the backflow into the primary was detectable because of the discoloration. However, secondary
medication backflow due to back-check valve failure is
generally not detectable. Additionally, once the primary
infusion resumes, the rate of delivery of the secondary
medication (which is now actually in the primary bag and
not in the patient) is determined by the programmed primary rate.
Lack of secondary medication delivery due to an inadvertently closed clamp is often not detected until the
next dose is due. Both of these errors result in either a
medication administration delay or a completely missed
dose.2,16,17

130   Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc.
on behalf of the Infusion Nurses Society.

Journal of Infusion Nursing

CASSETTE SYSTEM
Primary and secondary medication administration using a
cassette system is regulated by valves in the cassette. These
cassette valves eliminate the need for head-height differentials and a primary line back-check valve for secondary medication administration. Because the secondary medication
has its own fluid path, if the roller clamp is inadvertently
engaged during secondary medication administration, an
alarm will provide notification to the clinician. Thus, cassette
systems provide a technical mitigation for the 3 reasons
identified above for secondary medication administration
error that exist on the head-height differential systems.27

OBJECTIVE
Concerning secondary medication administration, this need
has already been recognized by ISMP in their recent guidelines for optimizing IV smart pumps safely, where they recommend the use of systems for secondary medication infusion
that do not require a head-height differential.13 The objective of this study was to measure the impact of medication
administration practices between 2 types of IV smart pumps
during actual clinical use. The BD/Alaris pump was used as
the representative head-height differential system and the
ICU Medical Plum 360 (ICU Medical, Inc., San Clemente, CA)
was used as the representative cassette system.

Because of the requirements for a primary line back-check
valve and the need to manually open the roller clamp
during secondary infusion with linear peristaltic technology, we hypothesized that there would be fewer secondary
medication administration delays with the cassette system
as compared with the head-height differential system.

STUDY DESIGN AND METHODOLOGY
Setting

The study design was observational and noninterventional.
Two large (600- and 800-bed) urban hospitals were used as
study sites, one that used the head-height differential system and one that used the cassette system. Observational
data collection occurred in both the critical care and
general medical–surgical clinical units in both study sites.
Institutional review board approval was obtained at each
site before beginning data collection, and data were collected at each site by a single observer.

Sample

Using a point prevalence methodology, data were collected
on a minimum of 100 medication observations at each site
(50 in medical–surgical and 50 critical care), which occurred
over a consecutive 2-day period. Observations using convenience sampling were recorded real-time using a case
report form (CRF).

Inclusion Criteria

RESEARCH AIMS AND HYPOTHESES
Aim 1

What is the adherence with the requirement of pump–primary IV head-height differential of 20 inches for the headheight differential system during actual clinical use?
Because of the complex setup requirements and limited
physical space during actual clinical use, we hypothesized
that the pump–primary IV head-height differential for
appropriate medication administration will be insufficient
at least 50% of the time during actual clinical use.

Aim 2

What is the adherence with the 9.5-inches secondary
head-height requirement with the head-height differential
system pump during actual clinical use?
We hypothesized that the required primary–secondary
head-height differential for appropriate medication administration will be insufficient at least 20% of the time during
actual clinical use.

Aim 3

Is there a difference in secondary medication administration delay between the head-height differential system and
cassette system during actual clinical use?
VOLUME 44  |  NUMBER 3  |   MAY/JUNE 2021

All adult patients (18 years or older) hospitalized in either
a medical–surgical or critical care unit and who had at least
1 active IV secondary medication order were eligible for
inclusion in the study.

Exclusion Criteria

Adult patients on the study units who did not have at least
1 active IV secondary medication order were excluded.

Procedures
1. Data collection was completed on 2 consecutive weekdays between the hours of 6:00 am and midnight to capture medication administration at various times during
the 24-hour cycle.
2. First, the individual site investigators at each site reviewed all current secondary medication orders in the
electronic health record (EHR) for patients on the critical
care and medical–surgical study units.
3. Secondary bag volume, infusion duration, and type of secondary medication were collected as descriptive data.
4. Direct observation of each secondary medication administration at the point of care was done at the site using the
head-height differential system only to assess the setup by:
a. Measuring the distance between the top of the IV
smart pump and the primary fluid level (which should
be 20 inches)
journalofinfusionnursing.com  131

b. The secondary head-height differential measured as
the distance from the top of the primary fluid level to
the top of the secondary fluid level (which should be
at least 9.5 inches).
c. Confirming the presence of a back-check valve on the
primary line
d. Observing the position (open/closed) of the secondary medication tubing roller clamp
5. Direct observation of each secondary medication administration at the point of care was then done on both
IV smart pump types to confirm the actual time of secondary medication administration.
6. Patient identification was confirmed for all observations only to verify the EHR medication orders, but
no protected health information was collected on the
CRF.
7. Each secondary medication observation was assigned
a study number, as this was considered as the unit of
analysis.
8. Using the ISMP guidance, medications were recorded
as given on time (±30 minutes from order time) or delayed (administered outside of the ±30-minute time
window).28

9. A medication was recorded as omitted medication only
if dosing was not completed before the time of the next
scheduled dose.
10. The names of all ordered medications were collected.

RESULTS
A total of 301 medication administration observations
were included in this study: 102 (34%) for the head-height
differential system (medical–surgical: N = 51; critical care:
N = 51) and 199 (66%) for the cassette system (medical–
surgical: N = 88; critical care: N = 111). Table 1 summarizes
the descriptive data for secondary bag volume, infusion
duration, and medication type.

Aim 1

What is the adherence with the requirement of pump–
primary IV head-height differential of 20 inches for the
head-height differential system during actual clinical use?
Tables 2 and 3 summarize the total and clinical unit-specific
data on the measured pump–primary IV head-height differentials, including 5 instances where the primary fluid level

TABLE 1

Summarized Frequency Data for Secondary Bag Volume, Infusion
Duration, and Medication Type by Therapeutic Class
Total

Head-height differential system

Cassette system

Secondary bag volume (mL)

N

%

N

%

N

%

50

70

23.0%

29

28.4%

41

20.6%

100

182

60.0%

57

55.9%

125

62.8%

150

6

2.0%

0

0.0%

6

3.0%

250

39

13.0%

15

14.7%

24

12.1%

400

1

0.3%

1

1.0%

0

0.0%

500

3

1.0%

0

0.0%

3

1.5%

Secondary infusion duration (min)

N

%

N

%

N

%

15

3

1.0%

3

2.9%

0

0.0%

30

152

50.0%

36

35.3%

116

58.3%

60

79

26.0%

19

18.6%

60

30.2%

90

24

8.0%

9

1.0%

15

7.7%

120

8

3.0%

1

1.0%

7

3.5%

180

4

1.0%

3

0.2%

1

0.0%

240

31

10.0%

31

30.4%

0

0.0%

Medication therapeutic class

N

%

N

%

N

%

Antibiotic

216

72.0%

81

79.4%

135

67.8%

Other anti-infective

23

8.0%

5

4.9%

18

9.0%

Electrolyte/vitamin

40

13.0%

13

12.7%

27

13.6%

Other

22

7.0%

3

2.9%

19

9.5%
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TABLE 2

TABLE 4

Measured Primary Head-Height
Differentials

Measured Secondary Head-Height
Differentials

Inches

Total sample
(N = 102)

Medical–surgical
(N = 51)

Critical care
(N = 51)

Inches

Total sample
(N = 102)

Medical–surgical
(N = 51)

Critical care
(N = 51)

Mean

5.8

5.1

6.5

Mean

12.3

12.5

12.2

Median

5.2

5.0

6.0

Median

12.0

12.0

12.0

SD

4.9

5.0

4.9

SD

3.6

4.0

3.1

Minimum

–4.0

–3.5

–4.0

Minimum

0.0

0.0

7.0

Maximum 16.0

15.0

16.0

Maximum

21.0

21.0

20.0

was located below the pump (4 in medical–surgical and 1 in
critical care). Data show that none of the observations for
the primary infusion setup were compliant with the headheight differential system setup requirements of 20 inches
between the pump and the primary IV head height.

Aim 2

What is the adherence with the 9.5-inch secondary
head-height requirement with the head-height differential system during actual clinical use? Tables 4 and 5
summarize the total and clinical unit-specific data on
secondary head-height differentials. Overall, 16% (N =
17/102) of the secondary head-height differentials were
found to be <9.5 inches, with only minor differences
between medical–surgical and critical care. Of the 17
secondary infusions that did not meet the recommended
head-height differential, 2 infusions in medical–surgical
were found to have a head-height differential of 0 inches,
whereas the remaining heights were between 7 and 9
inches (Table 6).

Aim 3

Is there a difference in secondary medication administration delay between the 2 IV smart pump types during actual
clinical use?

Back-check Valve

For the head-height differential system, it was found that
100% of the primary lines did contain a back-check valve.
For the cassette system, there is no need for a back-check
valve because the cassette prevents backflow.

Roller Clamp

For the head-height differential system, 1 clamp (1% of
observations) on the secondary line was found in the closed
position, resulting in an omitted secondary medication dose
that was not detected. For the cassette system, 2 clamps
(1%) were found to be in the closed position on initiation
of the secondary infusion. In both cases, the clinician was
alerted by the alarm, and no medication delay occurred.

DISCUSSION
The findings from Aim 1, primary head-height compliance,
should be of concern to all practicing clinicians in the acute
care setting. There were no observations where the primary
head-height requirements were met, and 5 of the primary
infusion bags were found to be hanging below the pump. Since
flow rate accuracy and delivery of primary and secondary
infusions are dependent on adhering to the manufacturers’
recommendations for the system setup, the impact of these
findings on the accuracy of medication delivery is unknown.
In the busy setting of acute care, nurses are required to continually balance complex and ever-changing patients care
requirements. Any time a technical versus a manual solution
can be used to improve the safety and efficiency of patient
care, it should be considered. Based on these findings, cassette
IV infusion technology provides an example of a technical solution that can improve both the quality and process of care for
secondary medication administration.

TABLE 5
TABLE 3

Adherence With Required Primary
Head-Height Differentials
Total frequency
(%)

Medical–surgical Critical care
frequency (%)
frequency (%)

Yes

0

0%

0

0%

0

0%

No

102

100%

102

100%

102

100%
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Adherence With Required
Secondary Head-Height
Differentials
Total
frequency (%)

Medical–surgical
frequency (%)

Critical care
frequency (%)

Yes

86

84%

45

88%

41

78%

No

16

16%

6

12%

11

22%
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TABLE 6

Head-Height Differentials for
Nonadherent Secondary Infusions
Inches

Medical–surgical

Critical care

0

2

0

7

1

1

8

1

2

9

2

8

For Aim 2, while the majority (84%) of secondary medication infusion setups did meet the 9.5-inch head-height
differential requirement, 16% did not, which is a considerable degree of error. The 2 observations of a 0-inch differential very likely led to delayed administration of the secondary medication, while the remaining inadequate head
heights had variable and unknown impacts on flow rate.
More recent 2017 BD/Alaris product recommendations do
not specify 9.5 inches as the differential needed to achieve
the hydrostatic pressure for secondary flow but alternatively describe the secondary more generally as needing to
be sufficiently higher.29 This open-ended recommendation
may lead to further inconsistency at the bedside, since no
clinical guidance is provided in those recommendations for
any operational definition of what sufficient means.
These findings provide evidence that it is difficult, if not
impossible in some situations, to comply with the recommendations for head height during actual clinical use of
head-height IV smart pump systems. Clinical realities, such
as limitations on space at the bedside, the availability and
type of IV poles, and head-height requirements that make
it impossible for most nurses to reach the IV bags without
standing on a stool, all contribute to the lack of compliance
with recommended head-height differential system setup.
To illustrate this point, Figure 2 shows the implications of

these setup requirements from the perspective of a frontline
nurse. The middle photo depicts the 9.5-inch secondary setup
requirement. These recommendations require frontline nurses to conform to physical setup requirements that are often
not possible at the bedside, which likely accounts for the 0%
compliance with primary head-height recommendations.
For Aim 3, we found a total of 3 closed clamps, 1 with
the head-height differential system that resulted in a missed
dose and 2 with the cassette system, both of which alarmed,
alerted the clinician, and did not result in missed doses.
Based on what is known regarding medication administration error with secondary infusion, errors of varying
severity are occurring during actual clinical use without
detection.16,17 These likely include reduced flow accuracy of
the secondary infusion due to inadequate hydrostatic pressure, concurrent flow of primary and secondary infusions,
backflow from the secondary into the primary due to backcheck valve failure, and, in this small sample, 1 documented
occurrence of a missed dose due to a closed clamp. While
data on the position of the pump relative to the patient
were not collected in this study, anecdotal observations
noted by the data collector found that the pumps were
positioned in a variety of locations relative to the patient,
including below the patient.
The impact on the delivery of antibiotics is concerning,
because the majority of medications (72%) administered by
secondary infusion were antibiotics (Table 1). When other
anti-infectives are included, the total is 80%. Incomplete
dosing of antibiotics not only decreases the therapeutic
benefit to the patient but also contributes to antibiotic
resistance due to the resultant subtherapeutic levels, which
foster bacterial mutation.30 While appropriate and timely
antibiotic administration as prescribed is always important,
in certain clinical situations like sepsis, where every hour
delay in antibiotic administration results in an 8% increase
in mortality,19 it can literally make the difference between
life and death.20,31,32

Figure 2 Using a commonly available intravenous pole and the 9.5-inch secondary hanger, if the recommendations for primary and secondary
head heights are followed, it is not possible for this 5′5″ nurse to reach the secondary medication bag. Images used with permission from Melody
Bennett, MN, RN.
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LIMITATIONS
This study was conducted in 2 hospitals that were chosen
to be similar in bed size, urban location, patient acuity, and
annual patient discharges. The findings from these 2 hospitals are not necessarily representative of the practices in all
US hospitals. The authors acknowledge that the study used
a point-prevalence, convenience sample design, and observational approach with data collected over a 2-day period,
so the findings should be interpreted in that context. As
the study was primarily descriptive in nature, a larger-scale
trial with multiple sites, additional IV smart pump types,
different size hospitals, and a larger sample size is needed
to more thoroughly describe IV smart pump medication
administration practices in a way that is more generalizable.
This is especially important to study the issue of medication delay. Even with these limitations, it is the authors’
hope that this study provides an example of the type of
practice-based research that can generate data from the
point of care to support improvement in IV medication
administration safety and inform future recommendations
for implementation science.

CONCLUSION AND IMPLICATIONS FOR
FUTURE RESEARCH
In addition to a larger-scale study, a knowledge assessment
of direct care nurses on the topic is warranted. It is important to learn more about the overall knowledge level of
these professionals concerning the technical requirements,
limitations, and clinical effects of secondary medication
administration and the potential for error. This information
is important for the development and implementation of
educational materials that may, at least in the short term,
help improve the secondary medication administration
process. However, even if frontline caregivers are provided with all the relevant knowledge, the current system
requirements for flow rate accuracy using head-height
differential systems are simply not possible to achieve consistently at the point of care. There is a need for additional
human-factors designed technology to replace manual
processes to improve the process of care for nurses and the
safety of care for patients.
Much more research is needed to understand the variations in flow rate accuracy under the conditions that actually exist in acute care, as reported data are generally limited to manufacturer recommendations and requirements.
Because most IV smart pumps were developed before the
current FDA requirements for human-factors safety testing,
there is a lack of practice-based flow rate data to help guide
clinical decision-making. ECRI, a noncommercial organization for health care technology assessment, regularly
publishes IV infusion comparative effectiveness reports and
issues recommendations. Their recent IV infusion report
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was released on March 18, 2020. Unfortunately, the ECRI
testing process uses only manufacturers’ recommendations
for setup, which provides no insight into what actually
happens in the clinical settings. Practice-based research on
flow rate accuracy using a variety of realistic clinical scenarios is needed to help clinicians understand which patient
safety and usability tradeoffs exist among the different IV
smart pump systems.
Finally, innovation in IV smart pumps to develop technical solutions for as many usability issues as possible is
needed, including the development of additional choices
that do not require a head-height differential for secondary medication infusion.3,32 With the high level of demand
for clinicians at the point of care, manufacturers have
the responsibility to improve both clinical workflow and
patient safety by creating innovative technology solutions
to improve IV smart pump usability in this very important
area of patient safety.
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